BRAF-targeted therapy and immune responses to melanoma

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Ngiow, Shin Foong ^a,b   Knight, Deborah A ^b,c   Ribas, Antoni ^d,e   McArthur, Grant A ^b,c   Smyth, Mark J ^a,f  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

BRAF; Checkpoint; Immunity; Melanoma; T cell

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; CD11B ANTIGEN; CD137 ANTIBODY; CHEMOKINE RECEPTOR CCR2; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAF GENE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE TRANSFER; MELANOMA; METASTATIC MELANOMA; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE N RAS; OVERALL SURVIVAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR REGRESSION;

EID: 84886945081     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24462     Document Type: Article

References (12)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi. org/10.1056/NEJMoa1103782
2. McArthur GA, Ribas A. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 2013; 31:499-506; PMID:23248252; http://dx.doi. org/10.1200/JCO.2012.45.5568
3. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012; 1:997-9; PMID:23189245; http://dx.doi.org/10.4161/onci.19865
4. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the antimelanoma activity of BRAF inhibitors. J Clin Invest 2013; 123:1371-81; PMID:23454771; http://dx.doi. org/10.1172/JCI66236
5. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012; 18:5329-40; PMID:22850568; http://dx.doi.org/10.1158/1078-0432.CCR-12-1632
6. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9; PMID:20551059; http://dx.doi. org/10.1158/0008-5472.CAN-10-0118
7. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010; 16:6040-8; PMID:21169256; http://dx.doi. org/10.1158/1078-0432.CCR-10-1911
8. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479
9. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494:251-5; PMID:23302800; http://dx.doi.org/10.1038/nature11814
10. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013; 19:598-609; PMID:23095323; http://dx.doi.org/10.1158/1078-0432.CCR-12-2731
11. Koya RC, Mok S, Otte N, Blacketor KJ, Comin- Anduix B, Tumeh PC, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72:3928-37; PMID:22693252; http://dx.doi.org/10.1158/0008-5472.CAN-11-2837
12. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19:393-403; PMID:23204132; http://dx.doi. org/10.1158/1078-0432.CCR-12-1626